Brand Name

TALTZ

Generic Name
Ixekizumab
View Brand Information
FDA approval date: March 22, 2016
Classification: Interleukin-17A Antagonist
Form: Injection

What is TALTZ (Ixekizumab)?

TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
Enrollment Status: Recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Phase: Phase 4

Summary: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

Proactive Therapeutic Drug Monitoring Versus Routine Care With the Novel Biologics in Psoriasis : a Pragmatic, Multicentric, Randomised, Controlled Study
Proactive Therapeutic Drug Monitoring Versus Routine Care With the Novel Biologics in Psoriasis : a Pragmatic, Multicentric, Randomised, Controlled Study
Enrollment Status: Recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Phase: Phase 4

Summary: Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23. Physicians always prescribe these drugs in a fixed dose, but this may lead to under- and overdosing in some patients. Underdosing may lead to inadequate response or loss of response over time. Overdosage, on the other hand, can lead to higher risk of side effects and highe...

A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.
A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Phase: Phase 4

Summary: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

View All Clinical Trials

Related Latest Advances

Interleukin-17A inhibitors for guttate psoriasis treatment: A retrospective cohort study.
Interleukin-17A inhibitors for guttate psoriasis treatment: A retrospective cohort study.
Journal: JAAD international
Published: April 13, 2026
Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature.
Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature.
Journal: Journal of drugs in dermatology : JDD
Published: April 03, 2026
Commentary on: "Ixekizumab with Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity".
Commentary on: "Ixekizumab with Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity".
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: March 31, 2026
View All Latest Advances